Log In
Print
BCIQ
Print
Print this Print this
 

Subcutaneous Remodulin

  Manage Alerts
Collapse Summary General Information
Company United Therapeutics Corp.
DescriptionSubcutanoeus formulation of synthetic long-acting stable prostacyclin analog
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHypertension
Indication DetailsTreat pulmonary arterial hypertension (PAH)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today